Beijing Balance Medical

Beijing Balance Medical makes animal-derived heart valves and patches that were the first domestically approved products in their fields.

: Public company
: 2005
: Beijing, CNChina

Library

balancemed.cnCrawled Oct 25, 2026

Product

6 pages

Congenital Heart Disease Treatment MORE +/en/lists/14.html
Devices/en/lists/3.html
Doctors/en/lists/4.html
Education/en/lists/5.html

Blog

5 pages

Beijing Balance Medical's 2023 "Financial Consumer Rights Protection Education and Publicity Month" event In accordance with the work requirements of the China Securities Regulatory Commission and the Beijing Securities Regulatory Bureau, the 2023 "Financial Consumer Rights Protection Education and P MORE +/en/article/12/182.html
Clinical follow-up summary and risk-benefit statistical analysis report of sold-out occluders. Follow-up results and statistical analysis report of 100 consecutive patients who underwent surgery since Regarding "organize the clinical follow-up status of all sold products and submit a summary report, which should include follow-up methods, average follow-up time, follow-up items and follow-up r MORE +/en/article/5/52.html
Hemifacial spasm: Conservative and surgical options Hemifacial spasm is a motor neurological disorder characterized by brief or sustained involuntary contractions of the muscles innervated by the facial nerve. The incidence rate is approximately 11/100 MORE +/en/article/5/54.html
Introduction of Beijing Balance Medical Closure Products for Heart Septal Defect Overview of cardiac septal defect closure in congenital heart disease: Cardiac septal defect is a general term for three common congenital heart diseases: ventricular septal defect, atrial septal defe MORE +/en/article/5/51.html

Press

4 pages

Careers & Hiring

1 page

Join us/en/lists/7.html

Team

1 page

Doctors/en/lists/16.html

About

2 pages

About us/en/content/2.html
Our Honour/en/content/9.html

Contact

1 page

Homepage

1 page

Homepage/
Bairen Medical develops and produces animal-derived biomaterial medical devices using proprietary tissue engineering and chemical modification techniques. The company holds 17 approved Class III medical device products, focusing on cardiovascular valve replacement and repair, congenital heart disease interventions, and surgical soft tissue repair.

Privacy

1 page

Terms & Conditions

1 page

Legal terms/en/article/40/75.html

Coverage

5 items

Beijing Balance Medical's Transcatheter Pulmonary Valve System Wins NMPA Approval – Third Innovative‑Device Clearance Redefines TPVR with Transthoracic Remodeling Approachflcube.com/beijing-balance-medicals-transcatheter-pulmonary-valve-system-wins-nmpa-approval-third-innovative-device-clearance-redefines-tpvr-with-transthoracic-remodeling-approach/
Beijing Balance Medical secures NMPA approval for its transcatheter pulmonary valve system, the third innovative device clearance from the regulator. The system targets patients needing transcatheter pulmonary valve replacement (TPVR) and introduces a transthoracic remodeling approach. The approval accelerates access to advanced interventional valve solutions in China.
Oct 2026Insight, China's Pharmaceutical IndustryNews article
Balance Medical ePTFE Pericardial-Membrane Gets NMPA Nod, Ends Import Relianceflcube.com/balance-medical-eptfe-pericardial-membrane-gets-nmpa-nod-ends-import-reliance/
Balance Medical Technology secures NMPA approval for its domestically produced expanded polytetrafluoroethylene (ePTFE) pericardial membrane, eliminating China’s dependence on imported cardiac surgery materials. The product supports cardiac procedures by providing a synthetic pericardial substitute. This approval marks a key milestone for domestic medical device innovation in China.
Dec 2025Insight, China's Pharmaceutical IndustryNews article
Beijing Balance Medical's Renato System Gets NMPA Approval for Valve-in-Valve Therapyflcube.com/beijing-balance-medicals-renato-system-gets-nmpa-approval-for-valve-in-valve-therapy/
Beijing Balance Medical secures NMPA approval for its **Renato Transcatheter Valve-in-Valve System**, the first globally commercialized device for **valve-in-valve (ViV) therapy**. The system treats high-surgical-risk patients with failed bioprosthetic valves, addressing complications like **structural valve deterioration (SVD)**. The approval enables the company to expand its interventional cardiac offerings in China.
May 2025Insight, China's Pharmaceutical IndustryNews article
Balance Medtech's Interventional Pulmonary Valve Receives Fast-Track Designation from NMPAflcube.com/balance-medtechs-interventional-pulmonary-valve-receives-fast-track-designation-from-nmpa/
Balance Medtech secures fast-track designation from China’s NMPA for its all-comer interventional pulmonary valve and delivery system. This is the company’s third interventional valve product to receive fast-track status in China, accelerating regulatory review for its in-house developed medical device.
Jan 2025Insight, China's Pharmaceutical IndustryNews article